PwPepwise

Tirzepatide

Weight Loss

a.k.a. Mounjaro · Zepbound

GLP-1 / GIP dual agonist

Tirzepatide is a once-weekly injectable medication that simultaneously activates two gut hormone receptors.

§Dosing at a glance

7 protocols · from the research
What it's forDoseHow oftenHowFor how long
Type 2 Diabetes (blood-sugar control)5 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.52 wks
Obesity (without diabetes)10 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.72–88 wks
Obesity with type 2 diabetes10 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.72 wks
Obstructive sleep apnea10 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.52 wks
heart failure and obesity15 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.—
fatty liver (metabolic-associated steatohepatitis)5 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.52 wks
Psoriasis with overweight/obesity (adjunct to ixekizumab)2.5 mg—SubcutaneousInjected just under the skin, into the fat layer.36 wks

Approximate values pulled from the research — double-check before dosing.

§01Summary

Tirzepatide is a once-weekly injectable medication that simultaneously activates two gut hormone receptors — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) — producing powerful effects on blood sugar control, appetite regulation, and body weight. Originally developed for type 2 diabetes, it has demonstrated broad cardiometabolic benefits across multiple conditions.

In large, well-controlled clinical trials, tirzepatide reduces body weight by up to 20.9% over 72 weeks in people with obesity1, and by 12.8–14.7% in people with obesity and type 2 diabetes4. It reduces HbA1c substantially and surpasses the glycemic control achieved with basal insulin6,8,13. Beyond weight and blood sugar, tirzepatide reduces the risk of worsening heart failure in people with obesity-related HFpEF5, dramatically lowers progression to type 2 diabetes in high-risk individuals2, reduces severity of obstructive sleep apnea7, and resolves liver inflammation in metabolic-associated steatohepatitis18. Weight regain is common after stopping treatment, underscoring that ongoing therapy is typically necessary for sustained benefit3. Gastrointestinal side effects such as nausea, vomiting, and diarrhea are the most common adverse effects and are generally mild to moderate in severity1,4,6.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Tirzepatide is a synthetic 39-amino acid acylated peptide that functions as a dual agonist at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R)9. Its molecular architecture is based on the native GIP peptide sequence but incorporates a modified amino acid backbone and a C20 fatty diacid moiety attached via a linker, enabling albumin binding that extends the plasma half-life to approximately 5 days and supports once-weekly subcutaneous dosing6,9.

At the GLP-1R, tirzepatide acts as a full agonist, stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon release from alpha cells, slowing gastric emptying, and activating central satiety pathways in the hypothalamus and brainstem — mechanisms shared with approved GLP-1 receptor agonists such as semaglutide. At the GIPR, tirzepatide acts as a full agonist in a manner that appears to confer additive or synergistic metabolic effects, including enhanced insulin secretion at postprandial glucose concentrations, improved insulin sensitivity in adipose tissue, and potentially direct effects on energy expenditure and adipogenesis. The integrated dual receptor engagement produces HbA1c reductions and weight loss that consistently exceed outcomes observed with selective GLP-1R agonists in head-to-head comparisons9,16.

Downstream metabolic consequences of tirzepatide's dual mechanism include dose-dependent reductions in fasting serum glucose, postprandial glucose excursions, body weight, visceral adipose tissue volume, hepatic steatosis, and circulating inflammatory markers such as hsCRP7,15. In the liver, tirzepatide reduces intrahepatic lipid content by 8.09% versus 3.38% with insulin degludec, with reductions correlating with baseline liver fat burden, weight loss, and visceral adipose tissue reduction15. Histological resolution of MASH occurs in 44–62% of treated patients at 52 weeks18, implicating both weight-loss-mediated and potentially weight-independent hepatic mechanisms.

Cardiac structural effects include reductions in left ventricular mass and paracardiac adipose tissue observed by cardiac MRI, with LV mass changes correlating with body weight reduction, LV end-diastolic volume changes, and left atrial volume changes19, suggesting both hemodynamic unloading and adipose depot-specific effects contribute to HFpEF benefit5. At the systemic level, tirzepatide produces clinically significant improvements in systolic blood pressure, lipid profiles, and markers of cardiovascular risk1,7. The glucose-dependent mechanism of insulin secretion means that hypoglycemia risk is inherently low in the absence of exogenous insulin or sulfonylureas, as insulin release diminishes when glucose approaches normoglycemia9,13.

§04Evidence & efficacy

Evidence base
257Studies
164Human
6Animal

Tirzepatide demonstrates strong and consistent efficacy across multiple metabolic and cardiometabolic indications, supported by replicated phase 3 RCT data.

Weight reduction in obesity: Tirzepatide reduces body weight by 15.0%, 19.5%, and 20.9% at 5 mg, 10 mg, and 15 mg respectively versus 3.1% for placebo at 72 weeks1. Between 85–91% of patients achieve ≥5% weight loss, and 50–57% achieve ≥20% weight reduction at the two higher doses1 — a magnitude previously associated only with bariatric surgery. When combined with prior intensive lifestyle intervention, tirzepatide produces an additional 18.4% weight reduction versus 2.5% regain on placebo11. Over 88 weeks of continuous therapy, mean total weight reduction reaches 25.3%3. Continued treatment is essential: discontinuation results in regain of approximately two-thirds of lost weight within 52 weeks, with only 16.6% of placebo-switched patients maintaining ≥80% of their prior weight loss versus 89.5% on continued tirzepatide3. Dose reduction to 5 mg provides a partial maintenance option14.

Type 2 diabetes glycemic control: Tirzepatide reduces HbA1c by 1.87–2.58% across multiple trials, consistently superior to placebo9, titrated insulin glargine6,13, basal insulin plus prandial insulin lispro8, and insulin degludec6. Between 75–93% of patients achieve HbA1c <7.0% across trials9,12. A network meta-analysis confirms tirzepatide produces the largest body weight reduction of any diabetes drug class evaluated (mean difference −8.57 kg; moderate certainty)16.

Diabetes prevention: In people with obesity and prediabetes followed for 176 weeks, tirzepatide reduces progression to type 2 diabetes by 93% relative to placebo (HR 0.07; 95% CI 0.0–0.1)2, with partial persistence of protection 17 weeks after treatment cessation2.

Heart failure with preserved ejection fraction: Tirzepatide reduces the composite of cardiovascular death or worsening heart failure by 38% (HR 0.62; P=0.026) in obese HFpEF patients, driven primarily by a 46% reduction in worsening heart failure events, and significantly improves health status as measured by KCCQ-CSS5. Cardiac MRI data show tirzepatide reduces LV mass by 11 g and paracardiac adipose tissue by 45 mL versus placebo19.

Obstructive sleep apnea: Tirzepatide reduces the apnea-hypopnea index by 20.0–23.8 events/hour versus placebo (P<0.001 in both trials), with accompanying improvements in hypoxic burden, systolic blood pressure, hsCRP, and patient-reported sleep outcomes7.

Liver disease (MASH): Tirzepatide achieves MASH resolution without fibrosis worsening in 44–62% of patients versus 10% on placebo at 52 weeks, with a clear dose-response relationship18.

Liver fat and visceral adiposity: Tirzepatide reduces liver fat content by 8.09% versus 3.38% with insulin degludec, and significantly reduces visceral and abdominal subcutaneous adipose tissue15.

Psoriasis with obesity (adjunct therapy): The combination of tirzepatide plus ixekizumab achieves simultaneous complete skin clearance (PASI 100) and ≥10% weight reduction in 27.1% of patients versus 5.8% with ixekizumab alone17.

§05Safety

Tirzepatide has a well-characterized safety profile established across more than 20 large phase 3 randomized controlled trials involving thousands of participants and treatment durations up to 176 weeks2.

The most consistently reported adverse events are gastrointestinal in nature — nausea, vomiting, diarrhea, decreased appetite, and constipation — occurring in roughly 12–26% of patients depending on dose and trial population1,4,6,8,9,10. These effects are predominantly mild to moderate in severity and arise most frequently during the dose-escalation phase, generally subsiding with time6,9. Treatment discontinuation due to adverse events is dose-dependent, ranging from approximately 4–7% across dose groups in obesity trials1, and up to 18% at the 15 mg dose in some add-on insulin trials10.

Hypoglycemia risk is notably low when tirzepatide is used without sulfonylureas or insulin. In monotherapy trials, no clinically significant or severe hypoglycemia was observed9. When used as add-on to basal insulin, hypoglycemia rates were approximately 11-fold lower than with prandial insulin lispro (0.4 vs. 4.4 events/patient-year)8, and substantially lower than insulin degludec (1–9% vs. 19%)6,13.

Cardiovascular safety has been assessed in high-risk type 2 diabetes patients, with a directionally favorable MACE-4 hazard ratio of 0.74 (95% CI 0.51–1.08) versus insulin glargine13. In HFpEF, tirzepatide reduced the composite of cardiovascular death or worsening heart failure5; however, cardiovascular mortality was numerically higher in the tirzepatide group (2.2% vs. 1.4%; HR 1.58, 95% CI 0.52–4.83), a finding based on small event numbers that was not statistically significant5.

No new safety signals were identified in a 3-year treatment period in the SURMOUNT-2 long-term extension2. Gastrointestinal adverse events leading to drug discontinuation occurred in 6.3% of tirzepatide patients versus 1.4% placebo in the HFpEF trial5. Safety has been confirmed in Asian populations, including Japanese patients, with a comparable adverse event profile12,20.

A network meta-analysis confirmed that tirzepatide's gastrointestinal adverse event burden is consistent with the GLP-1 receptor agonist drug class16.

§06History

Tirzepatide emerged from research into the gut incretin system, specifically efforts to engineer molecules capable of co-activating both the GIP and GLP-1 receptors simultaneously. The rationale was grounded in preclinical observations suggesting that combined GIP/GLP-1 receptor agonism could produce metabolic benefits — particularly for weight loss and glycemic control — exceeding those of selective GLP-1 agonism alone. Eli Lilly developed tirzepatide as a 'twincretin,' leveraging structural insights from native GIP peptide chemistry combined with acylation technology to achieve extended half-life compatible with weekly dosing.

The SURPASS clinical program, a large phase 3 development series, launched in 2019 and evaluated tirzepatide across five major trials comparing it to placebo, basal insulin, and GLP-1 comparators in type 2 diabetes. Landmark results from SURPASS-1 established phase 3 proof of concept in 20219, followed rapidly by SURPASS-2 through SURPASS-6 across diverse diabetes populations6,8,10,13. The FDA approved tirzepatide (branded Mounjaro) for type 2 diabetes in May 2022. The SURMOUNT obesity program produced pivotal weight-loss data in 20221, leading to FDA approval for chronic weight management (branded Zepbound) in November 2023. Subsequently, tirzepatide received FDA approval for obstructive sleep apnea in 20247, representing the first pharmacological approval for that indication. Ongoing trials are evaluating tirzepatide in HFpEF5, MASH18, diabetes prevention2, and combination dermatological indications17, substantially broadening its therapeutic landscape.

§07References